- Home
- CRVS vs MRVI Comparison
CRVS vs MRVI Comparison
Compare CRVS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- MRVI
- Stock Information
- Founded
- CRVS 2014
- MRVI 2014
- Country
- CRVS United States
- MRVI United States
- Employees
- CRVS N/A
- MRVI 560
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- MRVI Health Care
- Exchange
- CRVS Nasdaq
- MRVI Nasdaq
- Market Cap
- CRVS 305.4M
- MRVI 350.1M
- IPO Year
- CRVS 2016
- MRVI 2020
- Fundamental
- Price
- CRVS $5.75
- MRVI $2.42
- Analyst Decision
- CRVS Strong Buy
- MRVI Hold
- Analyst Count
- CRVS 4
- MRVI 10
- Target Price
- CRVS $15.00
- MRVI $5.84
- AVG Volume (30 Days)
- CRVS 518.7K
- MRVI 1.5M
- Earning Date
- CRVS 08-07-2025
- MRVI 08-11-2025
- Dividend Yield
- CRVS N/A
- MRVI N/A
- EPS Growth
- CRVS N/A
- MRVI N/A
- EPS
- CRVS N/A
- MRVI N/A
- Revenue
- CRVS N/A
- MRVI $219,830,000.00
- Revenue This Year
- CRVS N/A
- MRVI N/A
- Revenue Next Year
- CRVS N/A
- MRVI $7.23
- P/E Ratio
- CRVS N/A
- MRVI N/A
- Revenue Growth
- CRVS N/A
- MRVI N/A
- 52 Week Low
- CRVS $2.54
- MRVI $1.67
- 52 Week High
- CRVS $10.00
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- MRVI 49.60
- Support Level
- CRVS $5.28
- MRVI $2.28
- Resistance Level
- CRVS $5.64
- MRVI $2.47
- Average True Range (ATR)
- CRVS 0.30
- MRVI 0.14
- MACD
- CRVS 0.03
- MRVI -0.01
- Stochastic Oscillator
- CRVS 77.70
- MRVI 27.45
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.